FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, particularly production of recombinant proteins in Escherichia coli, and can be used for synthesis of human parathyroid hormone (rhPTH (1-34)). It involves constructing cDNA coding a fusion nucleotide ORF under control of an inducible promoter selected from a group consisting of araBAD, trp, T7, lac, Pho and trc, by cDNA amplification be means of RT-PCR with using gene-specific primers coding the rhPTH (1-34) fusion protein in which a fusion partner essentially consists of 41 amino acids produced of 124-164 amino acid of beta-galactosidase peptide (LacZ) Escherichia coli. Then the fusion protein is expressed in the presence of lactose as an inducer within 10-30% of total weight-based protein.
EFFECT: invention provides simplifying and reducing the price of rhPTH (1-34) synthesis ensured by optimising its expression in Escherichia coli.
12 cl, 15 dwg, 2 tbl, 16 ex
Authors
Dates
2012-01-27—Published
2007-12-06—Filed